Sub menu

 

 

Australian prescription medicine decision summaries

Search our decision summaries for the registration of new prescription medicines.

For more information, visit the About Australian prescription medicine decision summaries information page.

We have redesigned our prescription medicine decision summaries (AusPMDSs) to make it easier to understand how prescription medicines are registered in Australia. 

The redesigned AusPMDSs will offer clear, accessible information about recent medicine registration decisions.

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Published date

245 result(s) found, displaying 76 to 100

  • Intrarosa

    Prescription medicine decision summary
    ​TGA decision: Intrarosa (prasterone) is approved to treat vulvar and vaginal atrophy in postmenopausal women.

  • Esperoct

    Prescription medicine decision summary
    ​TGA decision: Esperoct (turoctocog alfa pegol) is approved to treat haemophilia A.

  • Gavreto

    Prescription medicine decision summary
    TGA decision: Gavreto (pralsetinib) is provisionally approved to treat adults with advanced or metastatic rearranged during transfection- fusion positive thyroid cancer.

  • Tibsovo

    Prescription medicine decision summary
    TGA decision: Tibsovo (ivosidenib) is approved to treat cancer.

  • Gavreto

    Prescription medicine decision summary
    TGA decision: Gavreto (pralsetinib) is provisionally approved to treat adults with locally advanced or metastatic rearranged during transfection fusion-positive non-small cell lung cancer.

  • Jivi

    Prescription medicine decision summary
    TGA decision: Jivi (damoctocog alfa pegol) is approved to treat adults and adolescents (12 years of age and older) with haemophilia A

  • Sunlenca

    Prescription medicine decision summary
    TGA decision: Sunlenca (lenacapavir sodium) is approved to treat multidrug resistant HIV-1 infection.

  • Radicava

    Prescription medicine decision summary
    TGA decision: Radicava (edaravone) is approved to treat adults with a diagnosis of amyotrophic lateral sclerosis.

  • Nuceiva

    Prescription medicine decision summary
    Nuceiva (prabotulinumtoxinA) is approved to treat glabellar lines.

  • Doptelet

    Prescription medicine decision summary
    Doptelet (avatrombopag maleate) is approved to treat thrombocytopenia in adult patients.

  • Mounjaro

    Prescription medicine decision summary
    Mounjaro (tirzepatide) is approved to treat diabetes.

  • Welireg

    Prescription medicine decision summary
    Welireg (belzutifan) is approved to treat adult patients with von Hippel-Lindau (VHL) disease

  • Evusheld

    Prescription medicine decision summary
    Evusheld (tixagevimab and cilgavimab) is approved to treat COVID-19

  • Prevenar 20

    Prescription medicine decision summary
    TGA decision: Prevenar 20 (Pneumococcal purified capsular polysaccharides) is approved to prevent pneumococcal disease.

  • Rybrevant

    Prescription medicine decision summary
    TGA decision: Rybrevant (amivantamab) is approved to treat lung cancer

  • Sotyktu

    Prescription medicine decision summary
    Sotyktu (deucravacitinib) is approved to treat plaque psoriasis.

  • Letybo

    Prescription medicine decision summary
    TGA decision: Letybo (letibotulinumtoxinA) is approved to treat the appearance of moderate to severe glabellar frown lines in adults.

  • Onpattro

    Prescription medicine decision summary
    Onpattro (patisiran) is approved to treat polyneuropathy.

  • Korsuva

    Prescription medicine decision summary
    Korsuva (difelikefalin acetate) is approved to treat chronic kidney disease

  • Vazkepa

    Prescription medicine decision summary
    Vazkepa (Icosapent ethyl) is approved to treat cardiovascular disease.

  • Vabysmo

    Prescription medicine decision summary
    Vabysmo (faricimab) is approved to treat macular degeneration.